13 Investment Institutions and Enterprises Actively Seeking Innovative Healthcare Projects — Selected Supply-Demand Matching Links
- VCBeat’s “Supply-Demand Matching” Industry Linkage Platform: Efficiently Connects Industry Resources to Drive Performance Growth
- To date, VCBeat has launched nearly 1,000 links, with each link receiving exposure1W+, achieving over successful corporate matchmaking instances2,000 times
- Continuously curate and publish collections of selected links, with precise distribution to VCBeat’s relevant professional communities (total reach exceeding3W+）
In the first half of 2024, the winter chill sweeping through the global healthcare investment and financing market entered a deeper phase, with limited capital increasingly flowing toward projects with clear market expectations. Nevertheless, innovation remains the core theme in the global healthcare sector, and various related initiatives continue to persuade investors on a large scale to enter the market.VCBeatCurated Supply-Demand Matchmaking Links – National Day Special，The theme of this issue is “Investment”。Let’s take a look at which types of innovative medical projects are favored by major capital enterprises and institutions. Details are as follows:
● Organization Profile：
Xien Investment focuses on investing in the consumer health sector. Since 2020, it has invested in third-party service companies with strong marketing and channel capabilities in the consumer health field, including industry-leading pharmaceutical Third-Party (TP) companies, well-known OTC marketing teams in the industry, and top-tier CID traffic acquisition agencies for major health products on Douyin. Starting in 2022, Xien Investment began investing in upstream product-oriented enterprises. On one hand, it seeks strategic partnerships with industrial groups that regard consumer health as a strategic sector; on the other hand, it invests in technology-driven companies or research teams with outstanding management, focusing on products that possess core technologies or high entry barriers, exhibit high repurchase rates, feature internet-operated attributes, and demonstrate proven efficacy.
● Proposed Investment Enterprises/ProjectsMu Huasuch as:
1. Field: Primarily engaged in industrial investment and mergers and acquisitions, with a focus on the out-of-hospital market, including health supplements, pharmaceuticals, and medical devices.
2. Stage: Targeting outstanding product-driven companies in the consumer health sector (Series A and earlier).
Kunyu Capital — Seeking Innovative Healthcare Companies in Need of Financing Support
● Organization Profile:
Kunyu Capital is an emerging research-driven investment bank, primarily focused on financing, investment, and M&A services in the healthcare and technology sectors. Its team members each possess over a decade of experience in venture capital and investment banking, demonstrating multidimensional, composite expertise in industry research, strategy, corporate finance, and risk identification and control. In the past, Kunyu Capital has helped multiple companies—including Chaomu Technology, Stream Data, Vhall Era, Zhangyou Tianxia, ZuGeLiang, and Xiaohei Consumption—complete multiple rounds of financing, thereby facilitating their forward-looking growth and development.
● Profile of Target Investment Enterprise/Project:
1. Sector: Focus on medical devices and healthcare services.
2. Stage: Pre-A to Series B; concurrently engage in M&A transactions with medical companies that are either publicly listed or part of industrial groups, and have an annual net profit exceeding RMB 20 million.
● Institution Profile:
After entering the Chinese market, the ZEISS Group has increased its investment in innovation projects. A notable example is the “Fengqi” project in Suzhou Industrial Park, which marks ZEISS’s first land acquisition and self-construction initiative in China, with a total investment of USD 25 million (approximately RMB 181 million). This facility will house the global B&C-class product center for the Microscopy Division, encompassing product management, R&D, manufacturing, and global distribution. It will also serve as a partial global production base for the Industrial Quality Solutions Division, along with a Customer and Solution Center for Greater China. In addition, ZEISS’s Meditec Division will add production capabilities for Class II medical devices, such as surgical microscopes and ophthalmic diagnostic equipment, while expanding global procurement operations for ZEISS headquarters and its various divisions.
● Profile of Target Investment Enterprise/Project:
1. Sector: Focus on domestic medical devices (ophthalmology and microsurgery, including implants), precision optical instruments, life science tools, industrial AI, and other sectors.
2. Stage: Early-stage innovation project.
● Organization Profile:
Jinding Capital, established in 2014, is a corporate venture capital (CVC) firm specializing in industrial investment. With cumulative funds under management approaching RMB 10 billion, the firm has long been deeply engaged in three core sectors: technology, big health, and consumer goods. Jinding Capital remains committed to cultivating highly specialized teams within niche industries through meticulous operations, partnering with outstanding enterprises to support their sustainable growth and enduring success.
● Profile of Proposed Investment Enterprise/Project:
1. Fields: Medical devices, medical materials, synthetic biology.
2. Stage: Companies with innovative technologies in the early stage, and companies with a certain revenue scale in the mid-to-late stages.
● Institution Introduction:
Ginkgo Valley focuses on the big data and cloud computing industries. It is China’s first fund built on data infrastructure and the first industrial capital to articulate and implement the strategic vision that “investing in cloud is investing in the future.” With data as a key element, it has grown into one of the leading early-stage investment firms in China, distinguished by its extensive portfolio, cutting-edge layout, rich ecosystem, and strong industrial focus in the big data and cloud sectors. Over the past decade, Ginkgo Valley has deployed billions of RMB in investments across more than 300 projects.
● Profile of Target Investment Enterprise/Project:
1. Domain: Includes the integration of large AI models with healthcare scenarios, healthcare informatics applications, and healthcare big data.
2. Stage: Primarily focusing on the early stage, while also taking into account the growth stage.
● Organization Profile:
Huayi Capital focuses on investments in the healthcare industry. Currently, Huayi manages funds that invest in projects at various stages, primarily concentrating on global early-stage, growth-stage, and M&A-phase healthcare ventures. While excelling in healthcare investment, Huayi aims to fulfill its social responsibilities and create industry influence, leveraging capital to drive medical transformation.
● Profile of Proposed Investee Company/Project:
1. Sector: Focus on scientific research instruments, CGT (Cell and Gene Therapy), and medical aesthetics; from a disease-specific perspective, favor conditions such as Parkinson’s disease.
2. Stage: Primarily focuses on healthcare projects in the early and growth stages globally, as well as those involved in mergers and acquisitions.
●Institution Profile:
Huajin Capital is the direct investment platform of Huafa Group, Zhuhai’s largest state-owned enterprise, which reported annual revenue of RMB 180 billion last year. Huajin Capital also serves as a limited partner (LP) in funds such as Honghui Healthcare Fund, Huagai Capital, IDG Capital, and Chende Capital. As a comprehensive investment institution with assets under management exceeding RMB 10 billion in direct investments, it focuses on three key sectors: healthcare, new energy, and semiconductors. To date, it has invested in nearly 50 biopharmaceutical and medical projects, covering various emerging technology areas and cultivating a robust portfolio ecosystem. In 2023, Huajin Capital ranked among the top 15 healthcare investment institutions by Zero2IPO Research.
● Profile of Target Investment Enterprise/Project:
1) Revenue-generating medical device companies, without specific sub-sectors.
2) Each single investment is approximately RMB 30 million.
3) Establishing operations in Zhuhai will come with more lenient conditions.
● Organization Profile:
Shenzhen GTJA Investment Group Co., Ltd. manages assets exceeding RMB 20 billion, operates 35 healthcare-focused funds, has invested in over 160 companies (including more than 90 in the healthcare sector), and facilitated the successful IPOs of 36 portfolio companies. With a China-based, globally oriented strategy, GTJA Investment has established operational centers in Shenzhen, Shanghai, Beijing, Hong Kong, and other locations. As a top-tier investor in the healthcare sector, it has made successful investments in companies such as Mindray Medical and United Imaging Healthcare.
● Profile of Target Investment Enterprise/Project:
1. Field: Innovative medical devices, etc.
2. Phase: Clinical Translation
● Company Profile:
Grand Pharma is a technology-driven, international pharmaceutical enterprise with core businesses spanning three major sectors: pharmaceutical sciences; radiopharmaceuticals for oncology diagnosis and therapy, and precision interventional diagnosis and therapy for cardiovascular and cerebrovascular diseases; and biotechnology. Grounded in the pharmaceutical and bio-industrial sectors, centered on patient needs, and powered by technological innovation, the company addresses unmet clinical demands by increasing investment in global innovative products and advanced technologies. It enriches and refines its product pipeline, strengthens and consolidates its industrial chain layout, and fully leverages its industrial advantages and R&D capabilities to provide more advanced and diverse treatment solutions for patients worldwide.
● Profile of Target Investment Enterprise/Project:
1. Field:
1) Manufacturers of amino acids, vitamins, and nucleoside raw materials
2) API Manufacturers
3) Bio-agriculture (pesticides, fertilizers, biostimulants), animal health, plant protection (bio-fertilizers)
4) Amino acid generic drug manufacturers (including approval documents)
5) Leading Companies with Advantages in Fermentation Platforms
6) Northern Fermentation Base (Including Monosodium Glutamate)
7) Companies with compounding and premixing technologies
2. Investment Methods
1) Equity + Agency 2) Mergers and Acquisitions 3) Joint Venture
● Organization Profile:
Since 2014, the Company’s stock and fund trading volume has ranked first in the industry (based on data from the Shanghai and Shenzhen Stock Exchanges); the monthly active users of its mobile wealth management app, “ZhangLe Fortune Pass,” have long topped the industry among apps, with cumulative downloads exceeding 70 million by the end of 2022; its equity underwriting, bond underwriting, and M&A restructuring businesses are among the industry leaders.
● Profile of Target Investment Enterprise/Project:
1. Sector: Medical devices and innovative drugs.
2. Stage: Primarily focused on early-stage projects.
● Organization Introduction:
United Future Capital is a China-based industrial investment firm specializing in niche healthcare sectors, with primary investment focuses including innovative drugs, innovative medical devices, high-value consumables, and healthcare services.As an LP with a background in industrial capital, it empowers its portfolio companies by identifying investment opportunities in niche sectors. It has already invested in a number of high-quality enterprises, including Baoji Pharmaceutical and Mantuoluo.
●Profile of Proposed Investment Enterprise/Project:
1. Sector: Innovative medical devices, consumables, medical aesthetics products, innovative drugs, etc.
2. Stage: Late-stage development; medical devices and consumables should have a certain scale, innovative drugs should have entered Phase III clinical trials, and medical aesthetics products should be able to obtain Class III certification within the next one to two years.
● Organization Introduction:
Since its establishment in 2011, Unity Ventures has remained focused on structural investment opportunities driven by technological transformation, distinguishing itself as one of the few early-stage technology venture capital firms in China that have consistently maintained an active and leading position while continuously evolving. The firm excels at identifying opportunities at the intersections of “Computing+” disciplines and cross-sector integration, with investments spanning Angel, Pre-A, and Series A rounds. Its strategic capabilities have been continually validated across sectors such as hard technology, artificial intelligence, advanced manufacturing, biotechnology, energy technology, new materials, and enterprise services.Unity Ventures has invested in nearly 300 portfolio companies, serving as an early investor in listed companies and unicorns including QingCloud (688316.SH), Airdoc (02251.HK), 36Kr (KRKR.US), Tanji, Zhonghe Yunke, and Momenta. The firm manages five RMB funds and one USD fund, with committed capital primarily sourced from founders of renowned domestic and international internet companies, market-oriented funds of funds, Chinese and foreign family offices, leading listed companies, and government guidance funds.
● Target Investment Enterprise/Project Profile:
Seeking to invest in pharmaceutical and medical device innovation enterprises led by experienced industry experts, dedicated to connecting with forward-thinking and innovative teams.
● Organization Profile:
In 1993, the flagship brand Beauty Farm was established. This brand isChina BeautyOne of the long-established domestic chain brands in the health management services industry. Subsequently, three emerging brands were established: Bellese, Yanyuan, and Showcare. As of June 30, 2022, Beauty Farm’s overall service network covered 352 stores, including 177 directly operated stores and 175 franchised stores.
● Profile of Target Investment Enterprise/Project:
Seeking investment opportunities in the consumer healthcare sector.
If you are interested in our products or have other enzyme engineering needs, please feel free to contact us immediately.
>>>>
① Interested in the above-mentioned companies' products, or currently monitoring products in other fields
② If you have innovative medical products and wish to participate in the weekly link promotion program
Welcome to scan the QR code below to contact us.
- VCBeat Supply-Demand Matching Platform covers: global expansion, supply chain, marketing/channels, technology transfer, and investment promotion/onboarding.
- Upload supply or demand resources via the platform to precisely reach target prospective partners
- Efficiently connect with MNCs, startups, government industrial parks, investment institutions, and other entities
>>>>
Download the VCBeat app to publish independently and connect efficiently.
